Sangamo Therapeutics has signed a definitive licence agreement with Voyager Therapeutics for a therapy to treat prion disease, a neurodegenerative condition. 

Sangamo has developed zinc finger transcriptional regulators (ZF-TRs) leveraging its epigenetic regulation platform. These ZF-TRs hinder the expression of the prion protein, which is the pathogenic driver of the disease. 

Sangamo has gained access to a capsid derived from the TRACER platform of Voyager. 

Under a non-exclusive licence, Sangamo will merge a Voyager TRACER capsid with its ZF-TRs for treating the condition. 

Sangamo will oversee the research, development, production and marketing of product candidates created using the Voyager capsid. 

Voyager will receive specific licence payments and royalty payments on possible commercial sales of any products leveraging its capsid.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the event that Sangamo out-licenses the prion programme, Voyager will receive a part of all licensing incomes linked to it. 

Sangamo will file an investigational new drug application in 2025 for a product candidate for prion disease.

Sangamo CEO Sandy Macrae stated: “While evaluating delivery mechanisms for our zinc finger transcriptional regulators, we were pleased to identify Voyager’s capsid as being well suited to potentially achieve the specific central nervous system coverage required for this indication today. 

“I’m excited to combine Sangamo’s cutting-edge epigenetic regulation capabilities with the delivery abilities of Voyager’s capsid to potentially create the first-ever meaningful therapy for prion disease.”